Rese Cel Autoimmune Follow Up Reaches One Year

Company Cabaletta Bio Event Type Updated clinical follow-up (SEC 8-K) Modality Autologous CD19 CAR T Asset Resecabtagene autoleucel (rese-cel) Target CD19 Disease Area Dermatomyositis; lupus nephritis; systemic sclerosis Summary Cabaletta disclosed updated single-arm rese-cel outcomes across autoimmune cohorts. Six of six dermatomyositis patients maintained immunomodulator-free…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *